Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
出版年份 2021 全文链接
标题
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-04-01
DOI
10.1038/s41571-021-00492-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
- (2021) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Single cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment
- (2020) Anuja Sathe et al. CLINICAL CANCER RESEARCH
- Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
- (2020) E. Van Cutsem et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations.
- (2020) Antoine Hollebecque et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
- (2020) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas.
- (2020) S. Derks et al. ANNALS OF ONCOLOGY
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer
- (2020) Yohei Kubota et al. CLINICAL CANCER RESEARCH
- The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1B–NTRK1 fusion
- (2020) Aya Shinozaki-Ushiku et al. Gastric Cancer
- Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
- (2020) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
- (2020) Anita Kulukian et al. MOLECULAR CANCER THERAPEUTICS
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients with Advanced Solid Tumors
- (2020) R. Bahleda et al. ANNALS OF ONCOLOGY
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- MET-dependent solid tumours — molecular diagnosis and targeted therapy
- (2020) Robin Guo et al. Nature Reviews Clinical Oncology
- 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
- (2020) K. Yamaguchi et al. ANNALS OF ONCOLOGY
- 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
- (2020) L.S. Wyrwicz et al. ANNALS OF ONCOLOGY
- LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
- (2020) N. Boku et al. ANNALS OF ONCOLOGY
- LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
- (2020) M. Moehler et al. ANNALS OF ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
- (2020) Yoshiaki Nakamura et al. NATURE MEDICINE
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
- (2020) Daniel V.T. Catenacci et al. Cancer Discovery
- Proteogenomic Characterization of Human Early-Onset Gastric Cancer
- (2019) Dong-Gi Mun et al. CANCER CELL
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).
- (2019) Daniel V.T. Catenacci et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
- (2019) Manish A. Shah et al. Gastric Cancer
- Enrichment of CLDN18 -ARHGAP fusion gene in gastric cancers in young adults
- (2019) Izuma Nakayama et al. CANCER SCIENCE
- Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase 3 study design
- (2019) Daniel VT Catenacci et al. Future Oncology
- Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.
- (2019) Xianbao Zhan et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- FRI-471-Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization
- (2019) Chia-Wei Chen et al. JOURNAL OF HEPATOLOGY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- (2019) Aparna R. Parikh et al. NATURE MEDICINE
- [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
- (2019) Tomomi Nakayama Iwata et al. PLoS One
- HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
- (2019) Akio Kaito et al. World Journal of Clinical Cases
- Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer
- (2019) Haisheng Zhang et al. Cancer Discovery
- Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
- (2018) S T Kim et al. ANNALS OF ONCOLOGY
- Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
- (2018) Yang Liu et al. CANCER CELL
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
- (2018) Bharat K.R. Chaganty et al. CANCER LETTERS
- The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
- (2018) Carolyn Hutter et al. CELL
- Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
- (2018) Takeru Wakatsuki et al. JOURNAL OF GASTROENTEROLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
- (2018) Yongjun Cha et al. Molecular Oncology
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
- (2018) Yoshiaki Nakamura et al. ONCOLOGIST
- Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma
- (2018) Steven B. Maron et al. Cancer Discovery
- E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
- (2018) Ilirjana Bajrami et al. Cancer Discovery
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
- (2018) Clara Montagut et al. JAMA Oncology
- Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
- (2018) De-Shen Wang et al. GUT
- The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).
- (2018) Satoshi Yuki et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- 103PPrevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
- (2018) D Moran et al. ANNALS OF ONCOLOGY
- 83POlaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
- (2018) Y-Z Liu et al. ANNALS OF ONCOLOGY
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
- (2018) K Muro et al. ANNALS OF ONCOLOGY
- A Multicenter Phase 2 Study of AMG 337 in Patients With MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other Solid Tumors
- (2018) Eric Van Cutsem et al. CLINICAL CANCER RESEARCH
- Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
- (2018) Shusuke Yagi et al. Gastric Cancer
- Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
- (2018) Seyoung Seo et al. Gastric Cancer
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
- (2018) Alicia Latham et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- Genomic loss of heterozygosity and survival in the REAL3 trial
- (2018) Elizabeth C. Smyth et al. Oncotarget
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
- (2017) Yasutoshi Kuboki et al. Gastric Cancer
- Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers
- (2017) Soo Young Cho et al. GASTROENTEROLOGY
- Germline Mutations in PALB2 , BRCA1 , and RAD51C , Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer
- (2017) Ruta Sahasrabudhe et al. GASTROENTEROLOGY
- Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
- (2017) Russell D. Petty et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
- (2017) Prabhsimranjot Singh et al. Journal of Hematology & Oncology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model
- (2017) Jiryeon Jang et al. Translational Oncology
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
- (2017) Jiwon Koh et al. Oncotarget
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
- (2016) Changqing Ma et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
- (2016) Charles S Fuchs et al. BRITISH JOURNAL OF CANCER
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
- (2016) V. Varadan et al. CLINICAL CANCER RESEARCH
- Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
- (2016) Sook Ryun Park et al. EUROPEAN JOURNAL OF CANCER
- Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients
- (2016) Akihito Kawazoe et al. Gastric Cancer
- HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
- (2016) F. Pietrantonio et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas
- (2016) Jia-Bin Liao et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases
- (2015) Rocco Cappellesso et al. HUMAN PATHOLOGY
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis
- (2015) FEI YUAN et al. ONCOLOGY REPORTS
- A mutational signature in gastric cancer suggests therapeutic strategies
- (2015) Ludmil B. Alexandrov et al. Nature Communications
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
- (2015) Sangjeong Ahn et al. Oncotarget
- Gastrointestinal malignancies harbor actionable MET exon 14 deletions
- (2015) Jeeyun Lee et al. Oncotarget
- Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity
- (2015) Fei Yao et al. Cell Reports
- Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract
- (2015) Olatunji B. Alese et al. Therapeutic Advances in Medical Oncology
- The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
- (2015) Ji Yun Lee et al. Scientific Reports
- Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer
- (2014) Yukinori Kurokawa et al. ANNALS OF SURGICAL ONCOLOGY
- Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
- (2014) Lin Shen et al. Gastric Cancer
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer
- (2014) Yukinori Kurokawa et al. Gastric Cancer
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
- (2014) Akiko Kawano Nagatsuma et al. Gastric Cancer
- Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
- (2014) Suling J Lin et al. GUT
- Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status
- (2014) Tao Wang et al. HUMAN PATHOLOGY
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
- (2014) Susan J Dutton et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
- (2013) N C T van Grieken et al. BRITISH JOURNAL OF CANCER
- Identification ofROS1rearrangement in gastric adenocarcinoma
- (2013) Jeeyun Lee et al. CANCER
- Physiological roles of Rho and Rho effectors in mammals
- (2013) Dean Thumkeo et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Improved survival of gastric cancer with tumour Epstein–Barr virus positivity: an international pooled analysis
- (2013) M Constanza Camargo et al. GUT
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions
- (2013) Nicola Fusco et al. MODERN PATHOLOGY
- Epstein-Barr Virus Infection as an Epigenetic Driver of Tumorigenesis
- (2012) A. Kaneda et al. CANCER RESEARCH
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
- (2012) Hee Eun Lee et al. EUROPEAN JOURNAL OF CANCER
- Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas
- (2012) Matteo Fassan et al. HUMAN PATHOLOGY
- Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
- (2012) Eun-Jung Jung et al. HUMAN PATHOLOGY
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas
- (2012) Eun Yoon Cho et al. MODERN PATHOLOGY
- Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
- (2011) C Bozzetti et al. BRITISH JOURNAL OF CANCER
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
- (2011) Stephen Lee et al. HISTOPATHOLOGY
- Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
- (2011) Min A Kim et al. HISTOPATHOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 status in unusual histological variants of gastric adenocarcinomas
- (2011) Giuseppe Giuffrè et al. JOURNAL OF CLINICAL PATHOLOGY
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER2 Testing in Gastric Cancer
- (2010) Luca Albarello et al. ADVANCES IN ANATOMIC PATHOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Microsatellite instability in colorectal cancer—the stable evidence
- (2010) Eduardo Vilar et al. Nature Reviews Clinical Oncology
- HER-2 amplification is highly homogenous in gastric cancer
- (2009) Andreas H. Marx et al. HUMAN PATHOLOGY
- PARP-1 Inhibition Prevents Oxidative and Nitrosative Stress–Induced Endothelial Cell Death via Transactivation of the VEGF Receptor 2
- (2008) Marlene T. Mathews et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now